Is Viberzi safe for long-term IBS-D treatment?

What are the safety concerns associated with long-term Viberzi use?

Viberzi (eluxadoline) is a prescription medication approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. [1] While Viberzi has been shown to be effective in reducing symptoms of IBS-D, there are certain safety concerns associated with its long-term use.

Potential liver toxicity and pancreatitis risks

One of the major concerns with long-term Viberzi use is its potential to cause liver toxicity and pancreatitis. Eluxadoline has been associated with an increased risk of acute pancreatitis, which can be a life-threatening condition. The risk of pancreatitis is higher in patients with a history of gallstones or those who drink heavily. [2] Patients taking Viberzi should be closely monitored for signs of pancreatitis, such as abdominal pain, nausea, and vomiting.

Risk of sphincter of Oddi dysfunction

Viberzi has also been linked to sphincter of Oddi dysfunction, a condition that can cause recurrent pancreatitis, abdominal pain, and bile duct obstruction. [3] This risk is particularly significant in patients who have a history of bile duct disease or gallstones.

Other safety concerns

In addition to the potential liver toxicity and pancreatitis risks, long-term Viberzi use has been associated with other safety concerns, including:

* Abdominal pain and diarrhea: While Viberzi is designed to reduce diarrhea, some patients may experience worsening abdominal pain and diarrhea as a result of long-term use.
* Muscle and joint pain: Some patients taking Viberzi have reported muscle and joint pain, which can be a significant concern for those with pre-existing musculoskeletal conditions.
* Serotonin syndrome: Although rare, there is a risk of serotonin syndrome, a potentially life-threatening condition caused by excessive levels of serotonin in the body.

Guidelines for safe use

While Viberzi can be a safe and effective treatment option for IBS-D, it's essential to follow guidelines for safe use to minimize the risk of adverse effects. These guidelines include:

* Close monitoring: Patients taking Viberzi should be closely monitored for signs of liver toxicity, pancreatitis, and other safety concerns.
* Dose adjustment: Patients who experience adverse effects may need to adjust their dose or switch to an alternative treatment.
* Regular check-ups: Regular check-ups with a healthcare provider can help identify potential safety concerns early, allowing for prompt intervention.

Patent status and biosimilar competition

The patent for Viberzi is set to expire in 2024 [4], which may lead to the development and marketing of biosimilar versions. Biosimilars are lower-cost alternatives that have been shown to be just as effective as the reference product. However, it's essential to note that biosimilars may not be available immediately after patent expiration, and regulatory approval may be required before they become available.

References:

[1] FDA. (2015). Eluxadoline tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
[2] FDA. 2017 Label update Viberzi (eluxadoline).
[3] Drugs.com. Sphincter of Oddi Dysfunction (SODD).
[4] DrugPatentWatch.com. Eluxadoline Patent Expiration Date

Sources:

1. FDA (Food and Drug Administration). (2015).
2. FDA. (2017).
3. Drugs.com.
4. DrugPatentWatch.com.